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People that develop extracranial cancers often display co-morbid neurological disor-
ders, such as anxiety, depression and cognitive impairment, even before commence-
ment of chemotherapy. This suggests bidirectional crosstalk between non-CNS
tumours and the brain, which can regulate peripheral tumour growth. However, the
reciprocal neurological effects of tumour progression on brain homeostasis are not
well understood. Here, we review brain regions involved in regulating peripheral
tumour development and how they, in turn, are adversely affected by advancing
tumour burden. Tumour-induced activation of the immune system, blood–brain bar-
rier breakdown and chronic neuroinflammation can lead to circadian rhythm dysfunc-
tion, sleep disturbances, aberrant glucocorticoid production, decreased hippocampal
neurogenesis and dysregulation of neural network activity, resulting in depression
and memory impairments. Given that cancer-related cognitive impairment diminishes
patient quality of life, reduces adherence to chemotherapy and worsens cancer prog-
nosis, it is essential that more research is focused at understanding how peripheral
tumours affect brain homeostasis.
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1 | INTRODUCTION
People that develop non-CNS tumours often acquire a variety of
affective and cognitive symptoms, including depression, anxiety and
cancer-related cognitive impairment (CRCI). Metabolic dysfunction
and sleep disturbances are also common co-morbidities that could
exacerbate cancer-related memory and mood disorders. These
adverse effects have long been attributed to the side effects of anti-
neoplastic treatments (Ahles & Root, 2018; Lange, Joly, et al., 2019).
However, longitudinal clinical studies now often include pretreatment
assessments and are beginning to detect affective and cognitive disor-
ders in cancer patients with non-CNS tumours prior to surgery or the
administration of antineoplastic therapy, including radiotherapy,
chemotherapy and/or hormonal therapy (Ahles et al., 2008; Berman
et al., 2014; Janelsins et al., 2014; Jansen et al., 2011; Olson &
Marks, 2019; Wefel et al., 2004). Importantly, the studies mentioned
here have controlled for confounding demographic variables, as well
as the cognitive reserve of individuals.
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Recently, the CNS has been shown to be a critical contributor to
tumour initiation and progression, via both direct and indirect modula-
tion of the tumour micro-environment (TME) (Faulkner et al., 2019;
Mauffrey et al., 2019). The relatively new field of Cancer Neuroscience
aims for a better understanding of the complex interactions between
the TME and the nervous system, specifically the influence of periph-
eral neuronal activity in both tumour initiation and cancer progression
(Monje et al., 2020). Neurotransmitters and their receptors are also
being investigated as novel and promising therapeutic targets to halt
tumour growth. However, the reciprocal effects of tumour growth on
the CNS and brain are being largely overlooked. The existence of pre-
treatment cognitive and affective disorders in people with non-CNS
cancers indicates a bidirectional crosstalk between the TME and CNS,
which is likely to occur indirectly, via modulation of the innate
immune system, and/or directly, through neurotransmitter release
(Monje et al., 2020; Olson & Marks, 2019). However, even though
cancer-associated neurological disturbances have been reported in a
variety of pretreatment peripheral cancers, the mechanisms underly-
ing these phenomena are still unknown (Baekelandt et al., 2016;
Berman et al., 2014). A better understanding of how extracranial
tumour growth leads to neurological complications is critical to
enhancing patient survival. Cancer-associated neurological distur-
bances often decrease the quality of life of people diagnosed with
cancer, and this can have knock-on effects, such as reducing patient
adherence to chemotherapy drug regimens and decreasing overall sur-
vival rates (Bender et al., 2014; Janelsins et al., 2014). Here, we review
how different brain regions are involved in tumour progression and
how they, in turn, can be adversely affected by peripheral tumour
growth (Table 1).
2 | BLOOD–BRAIN BARRIER
The blood–brain barrier (BBB) is formed by microvascular endothelial
cells, which line the cerebral capillaries of the brain and spinal cord.
The BBB plays a critical role in protecting the brain parenchyma from
blood-borne molecules and cells (Kadry et al., 2020). Peripheral
tumours are thought to affect brain function via disruption of the BBB
and peripheral immune cell infiltration (Olson & Marks, 2019)
(Figure 1). The BBB is highly plastic and is known to undergo signifi-
cant modification in response to physiological and pathological stimuli
(Erickson & Banks, 2018). Impairment of the BBB has been reported
in various CNS pathologies and particularly those initiated by
inflammation (Wardill et al., 2016). The neuro-damaging capabilities of
immune cell-derived pro-inflammatory cytokines are well
characterised, and they are gaining more and more attention as the
primary drivers of chemotherapy- and cancer-associated cognitive
impairment. Although the neurotoxic side effects of chemotherapy
were thought to be the main cause of BBB disruption in patients with
cancer, the inflammatory environment created by the tumour itself is
now being investigated as the initial source of BBB dysfunction. For
example, some cytokines, such as IL-1β alter the paracellular barrier
via breakdown and translocation of tight junction proteins, whereas
other cytokines, such as TNF-α, mainly target the intracellular
caveolae. Moreover, peripheral tumours could activate MMPs, via the
release of pro-inflammatory cytokines, which further disrupt the base-
ment membrane and tight junctions of the BBB (Kadry et al., 2020;
Wardill et al., 2016). When BBB integrity is compromised, solutes and
immune cells from the periphery can cross over to the brain more
easily, where they can disrupt cognitive function (Geng et al., 2018).
Tumour-induced peripheral inflammation was also shown to
induce astrogliosis in the brains of mice bearing Lewis lung carcinoma
(Demers et al., 2018). Astrocytes are intimately linked with endothelial
cells of the BBB via the direct contact of astrocyte endfeet with
pericyte cells that wrap around CNS vasculature. Therefore, astro-
cytes are acutely tuned to sense changes in BBB permeability
(Heithoff et al., 2021), although the exact contribution of astrocytes
to the maintenance of BBB integrity remains disputed (Kubotera
et al., 2019). Demers et al. (2018) evaluated BBB integrity and
observed increased accumulation of fibrin levels around cerebral vas-
culature and subsequent endothelial cell activation, potentially via
endothelial granule release of von Willebrand factor (VWF) (Demers
et al., 2018). More recently, in a mouse model of pancreatic ductal
adenocarcinoma, increased circulating immune cell infiltration was
observed in conjunction with extensive neuroinflammation and
cancer-associated cachexia (Burfeind, Zhu, Norgard, Levasseur,
Huisman, Buenafe, et al., 2020a). Here, a distinct population of non-
CNS neutrophils (CD45highCD11b+) expressing the chemokine
receptor CCR2 were shown to accumulate at the meninges
surrounding the hippocampus (known as the velum interpositum) of
tumour-bearing mice. Pharmacological blockade of CCR2 prevented
the circulating neutrophils from entering the brain and reduced the
symptoms of cancer-associated cachexia. The authors further showed
that tumour-derived factors induced the expression of the chemokine
CCL2 in brain macrophages, providing a potential mechanism underly-
ing the recruitment of CCR2 expressing neutrophils to the brain
(Burfeind, Zhu, Norgard, Levasseur, Huisman, Buenafe, et al., 2020a).
BBB integrity is also known to be disrupted by the release of
extracellular vesicles (EVs) in systemic inflammatory diseases
(Saint-Pol et al., 2020) (Figure 1). EVs are defined as membrane-
derived vesicles (including apoptotic bodies, microvesicles and
exosomes) and have been identified as important mediators of cell
communication via the exchange of lipids, nucleic acids and protein
products. Peripherally derived EVs can easily cross the BBB via the
circumventricular organs and endothelial transcytosis (Balusu
et al., 2016). Given the fact that a heterogeneous population of EVs
are being released during tumour growth, their potential involvement
in disrupting brain function in people with extracranial cancers is now
receiving much attention (Koh et al., 2020). Recently, Morad
et al. (2019) discovered that breast cancer-derived EVs can indeed
cross the BBB via caveolin-independent endocytosis. Using a mouse
model of triple-negative MDA-MB-231 cancer cells, the tumour-
derived EVs were shown to down-regulate the expression of the late
endosomal marker Ras-related protein 7 (Rab7) in brain endothelial
cells, demonstrating the ability of tumour-derived EVs to compromise
BBB integrity and enhance EV-mediated communication between the
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TABLE 1 A non-exhaustive list of rodent studies showing peripheral tumour-induced affective and cognitive disturbances, including central
dysregulations in the BBB, hippocampus, hypothalamus and VTA







Lewis lung carcinoma (LLC) in
female C57BL/6J mice
Accumulation of fibrin in
brain vasculature
Astrocyte activation (" GFAP)
à Anxious and depressive-
like behaviour
(Demers et al., 2018)
Pancreatic ductal
adenocarcinoma in male









Buenafe, et al., 2020a)
Triple-negative breast cancer
(human MDA-MB-231) in
female nu/nu nude mice
Tumour-derived EVs cross the
BBB via transcytosis and
down-regulation of
endothelial Rab7
(Morad et al., 2019)
Triple-negative breast cancer
(human MDA-MB-231) in




(Morad et al., 2020)






tumours in female Wistar
rats
Hippocampal inflammation
(" IL-1β, IL-6, TNF-α and
IL-10 protein)
à Anxious and depressive-
like behaviour
(Pyter et al., 2009)
Colon carcinoma (CT26) in
female BALB/c mice
Hippocampal inflammation
(" IL-6 and TNF-α mRNA)
# Hippocampal neurogenesis




(Yang et al., 2014)
Colon adenocarcinoma (C26)




à Fatigue and depressive-like
behaviour
(Norden et al., 2015)
Mammary tumours (67NR,
4T07 or 4T1) in female
BALB/c mice
Hippocampal inflammation
(" IL-1β protein and mRNA)
No effect on hippocampal
neurogenesis




(Walker Ii et al., 2017)
Mammary tumours (67NR) in
female BALB/c mice
No hippocampal inflammation
(= IL-1β, TNF-α, IFN-γ and
IL-6 mRNA)
(Emmer et al., 2019)














(Masri et al., 2016)







(Borniger et al., 2018)
Mammary tumours (67NR) in
female BALB/c mice
Disrupted central clock gene
regulation (Clock and Per1
mRNA)
(Sullivan et al., 2019)
(Continues)
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systemic circulation and CNS parenchyma (Morad et al., 2019). In a sub-
sequent study, the group worked on elucidating the functional conse-
quences of tumour-derived EV transport across the BBB (Morad
et al., 2020). Astrocytes were found to be themain recipients of periph-
eral EVs within the brain via the non-canonical Cdc42-dependent,
clathrin-independent carriers (CLIC)/GPI-anchored protein-enriched
early endosomal compartment (CLIC/ GEEC) endocytosis pathway.
Upon tumour-derived EV infiltration, astrocytes were found to express
significantly less tissue inhibitor of MMP-2 (TIMP2), which was hypo-
thesised to promote a suitable micro-environment for growth of brain
metastases. The authors further determined the EV factors that were
driving the decrease in TIMP2 in astrocytes by evaluating a number of
microRNAs (miRNAs) with the ability to target the 30-untranslated
region (30-UTR) within the TIMP2 mRNA. A miRNA known as miR-
301a-3p was found to be significantly increased in vitro and in vivo
(Morad et al., 2020). Although the authors did not investigate the
potential neurological effects of this EV-mediated decrease in TIMP2
expression and BBB disruption, it is likely that this could cause cogni-
tive impairment. In the context of brain ageing, a decline in plasma and
hippocampal TIMP2 levels is thought to be associated with age-related
cognitive dysfunction. Systemic administration of TIMP2 was shown to
increase hippocampal synaptic plasticity and to improve behaviour and
memory function in aged mice (Castellano et al., 2017). Moreover,
several miRNAs have already been identified for their involvement in
neuropathological diseases. For example, cerebral miR-30 directly
impairs hippocampal synaptic transmission and plasticity, and
miR-301b was shown to accelerate microglial activation and cognitive
impairment (Song et al., 2019; Tang et al., 2019). These findings suggest
that tumour-derived EVs could contribute to tumour-associated neuro-
logical disorders through the shuttling of miRNAs that disrupt BBB
integrity and/or directly alter neuronal function. Further investigation
of tumour-derived brain-infiltrating EVs and their contents is likely to
uncover more mediators capable of causing affective and cognitive dis-
orders in cancer patients (Koh et al., 2020).
3 | HIPPOCAMPUS
Although there is little evidence of direct crosstalk between the
periphery and the hippocampus, this limbic structure is one of
the main brain regions investigated in studies of CRCIs and mood dis-
orders in pretreatment cancer patients. This is due to the critical role
of the hippocampus in the processing of sensory stimuli and in mem-
ory formation, consolidation and retrieval (Opitz, 2014). Moreover,
the dentate gyrus of the hippocampus is one of only a few brain
regions that display lifelong neurogenesis, a process particularly
TABLE 1 (Continued)
Brain region Main function Cancer model Primary findings References


















Melanoma (B16F10) in male
OF1 mice
Central inflammation (" IL-6
and TNF-α mRNA)
# Dopaminergic and
serotonergic VTA input to
striatum and prefrontal
cortex
(# DOPAC, DA, 5-HT and
5-HIAA)
à Depressive-like behaviour
(Lebeña et al., 2014)
Lewis lung carcinoma (LLC)




and decreased NA levels in
the bone marrow
(Ben-Shaanan et al., 2018)
Mammary tumours (MDA-
231 and MCF-7) in male
BALB/c nude mice
Optogenetic VTA activation






(Xu et al., 2020)
Abbreviations: 5-HIAA, 5-hydroxy indoleacetic acid (serotonin metabolite); BDNF, brain-derived neurotrophic factor; DA, dopamine; DOPAC,
3,4-dihydroxyphenylacetic acid (dopamine metabolite); EVs, extracellular vesicles; GFAP, glial fibrillary acidic protein; HO, hypocretin/orexin; mPFC, medial
prefrontal cortex; NA, noradrenaline; TIMP-2, tissue inhibitor of MMP-2.
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important in the positive mood-enhancing mechanism of action of
several antidepressant medications (Kang et al., 2015). To date, most
neuroimaging studies in humans with non-CNS tumours have focused
on chemotherapy-related brain abnormalities, such as the diffuse
decrease in grey and white matter volumes, the decrease in neuronal
stem cell (NSC) proliferation in the dentate gyrus and subtle inward
deformation of the hippocampus, which correlates with self-reported
impairments in episodic memory (Deprez et al., 2018; Simo
et al., 2013). However, there is also evidence for the presence of
structural and functional hippocampal changes in chemotherapy-naïve
cancer patients, including hippocampal atrophy and the inability to
deactivate regions within the posterior cingulate, which receives input
from the hippocampus (Berman et al., 2014; Cimprich et al., 2010;
Perrier et al., 2020; Scherling et al., 2012). Moreover, the cognitive
domains that are commonly affected in people with non-CNS cancer
before treatment, such as working memory, explicit memory,
processing speed and executive function, all point towards the pres-
ence of hippocampal aberrations (Hermelink et al., 2007; Lange, Léger,
et al., 2019; Meyers et al., 2005; Wefel et al., 2004). Given that
increased levels of circulating inflammatory factors have been posi-
tively associated with cognitive dysfunction in people with cancer,
prior to chemotherapy (Cheung et al., 2015; Lyon et al., 2016; Patel
et al., 2015), and that the hippocampus is particularly vulnerable to
stress and inflammation (Conrad, 2008), researchers have suggested a
role for tumour-induced inflammation in pretreatment hippocampal
dysfunction (Santos & Pyter, 2018; Schrepf, Lutgendorf, &
Pyter, 2015). However, confounding factors, such as tissue trauma-
related stress responses, anaesthesia-mediated immune suppression
and opportunistic infection-driven systemic inflammation after sur-
gery, can complicate the interpretation of these findings and make it
difficult to attribute cognitive dysfunction directly with tumour
burden-associated inflammation (Emmer et al., 2019; Joly et al., 2015;
Kim, 2018; Lange, Léger, et al., 2019). Although the direct effects of
peripheral tumour growth on the hippocampal formation is unclear in
humans, several rodent studies support tumour-associated inflamma-
tion as a potential mechanism for hippocampal dysfunction (Norden
et al., 2015; Pyter et al., 2009; Santos et al., 2019; Yang et al., 2014).
Tumour-associated systemic inflammation has been a major focus
in trying to decipher the causes of pretreatment CRCI in people diag-
nosed with peripheral cancers. Of note, a wide variety of inflamma-
tory mediators, including but not limited to IL-1β, IL-6 and TNF-α,
have been associated with the systemic inflammatory response of
peripheral cancers (Colotta et al., 2009). Pyter et al. (2009) observed a
significant increase in hippocampal protein expression of IL-1β, IL-6,
F IGURE 1 Peripheral tumour growth can affect blood–brain barrier (BBB) integrity via the secretion of pro-inflammatory mediators, immune
cell activation and extracellular vesicles (EVs). Under normal circumstances, the BBB is constituted by endothelial cells, pericytes (not depicted), a
basal membrane and astrocytic endfeet. The endothelial cells of the CNS are held together by tight junctions, which are formed by
transmembrane molecules including claudins and occludins. These transmembrane adhesion complexes are linked to the cytoskeleton via
cytoplasmic adaptor proteins, such as zonula occludens-1 (ZO-1). In response to peripheral tumour growth, BBB integrity is thought to be
compromised via the release of pro-inflammatory cytokines (e.g., TNF-α and IL-1β) and MMPs. Increased fibrin deposition, immune cell infiltration
and the transcytosis of tumour-associated EVs could cause further tight junction and basal membrane disruption. However, the exact effects of
tumour-induced disruption of BBB integrity on cognitive and affective brain function require further elucidation. Figure was created with
BioRender.com
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TNF-α and IL-10 expression in rats with N-nitroso-N-methylurea
(NMU)-induced mammary tumours. Here, tumour-bearing mice
showed depressive-like behaviour based on the Porsolt forced swim
test, which was not observed by NMU exposure alone (i.e., before
tumour development), indicating that tumour growth itself was
responsible for the central inflammatory response (Pyter et al., 2009).
The increased production of pro-inflammatory cytokines in response
to tumour growth is thought to signal to the brain via humoral and
neural signalling (Dantzer, 2018). IL-10 is classically known as an anti-
inflammatory cytokine. However, the role of IL-10 in cancer is
ambiguous, and it teeters between immune stimulation and immune
suppression (Zhao et al., 2015). Yang et al. (2014) assayed the serum
levels of circulating cytokines in a BALB/c mouse model 2 weeks after
inoculation with a colon carcinoma cell line (CT26) (Yang et al., 2014).
In this study, an increase in the levels of serum IL-6 was observed, as
well as increased mRNA levels of hippocampal IL-6 and TNF-α, which
correlated with a decrease in the numbers of proliferating hippocam-
pal neurons and a decrease in the mRNA levels of brain-derived
neurotrophic factor (BDNF) and COX-2 in the hippocampus. In this
study, tumour-inoculated mice showed depressive-like behaviour in
the tail suspension test. This study suggests that peripheral tumour
growth alone can cause neurological dysfunctions through IL-
6-mediated inflammatory signalling, a reduction of hippocampal neu-
rogenesis and decreased levels of hippocampal BDNF and COX-2
(Yang et al., 2014). However, although this study by Yang et al. (2014)
suggests that depressive-like behaviour and memory impairments
may be attributed to a decrease in hippocampal COX-2 expression,
contrasting findings have been observed in tumour-bearing mice
treated with low dose-aspirin. Aspirin, an anti-inflammatory non-
selective COX inhibitor, prevented tumour-induced memory impair-
ments, although it did not affect tumour-induced sickness or tumour
growth, in 4T1 or EO771 mammary tumour mouse models (Walker
et al., 2018). Moreover, human studies suggest that using aspirin in
the year prior to receiving a cancer diagnosis reduced the risk of
developing depression, anxiety and stress-related disorders in the
year following a cancer diagnosis (data were adjusted for
sociodemographic factors, co-morbidities and cancer characteristics).
Interestingly, aspirin was more protective than other non-steroidal
anti-inflammatory drugs (NSAIDs) (Hu et al., 2020). Furthermore, the
decrease in hippocampal BDNF mRNA that was observed in
CT26-induced colon carcinoma by Yang et al. (2014) was not
extended to other tumour models, including 4T07 and 4T1 mammary
tumour models (Walker Ii et al., 2017) and NMU-induced ductal mam-
mary tumours (Pyter et al., 2010). These observations highlight that
tumour-induced changes in the hippocampus are highly cancer
specific.
Using the C26 colon adenocarcinoma in vivo model, Norden
et al. (2015) observed an increase in fatigue and depressive-like
behaviour in the voluntary wheel running activity paradigm and in the
sucrose preference and forced swim tests (Norden et al., 2015). They
report that the increase in cancer-related fatigue and depression was
associated with an increase in pro-inflammatory IL-1β and IL-6
mRNA expression in the cortex and hippocampus. Microglial
immunoreactivity was also significantly increased in the cortex,
although no changes were observed in the hippocampus (Norden
et al., 2015). This suggests an increase in neuroinflammation and
microglial priming in the brain in response to peripheral colon cancer.
More recently, Santos et al. (2019) examined changes in neuro-
inflammatory markers in response to mammary tumour growth and in
response to an additional LPS-mediated immune challenge (Santos
et al., 2019). Moreover, the extent to which mammary tumour re-
section could attenuate the tumour-induced neuroinflammatory
response was also investigated. An in vivo mouse model of non-
metastatic mammary carcinoma (67NR cell line in BALB/c mice) was
used. This was important to differentiate between the effects of
peripheral tumour burden and blood-borne metastatic cancer cells
that can invade and grow in CNS tissue. The protein levels of circulat-
ing TNF-α, IL-1β and IL-6 markedly increased in the plasma of both
control and tumour-bearing mice following LPS stimulation. However,
in the brain, the tumour-bearing cohort showed an attenuated neuro-
inflammatory response following peripheral immune challenge, com-
pared with control mice. Although the mRNA levels of TNF-α, IL-1β
and IL-6 increased in the hippocampus, hypothalamus and frontal cor-
tex of control mice, this inflammatory response was much weaker in
the brains of tumour-bearing mice following LPS stimulation. This is
interesting in the context of the large body of literature describing
how peripheral cancer growth is largely immunosuppressive and that
immune modulation is a mechanism employed by tumours to evade
destruction by cells of the innate immune system (Nguyen &
Spranger, 2020). Interestingly, tumour resection restored the neuro-
inflammatory response to a peripheral immune challenge, measured
as raised levels of hippocampal IL-6 and IL-1β, but not TNF-α. Their
results indicate that peripheral tumour growth can significantly
dampen neuroinflammatory pathways in the brain. However, no base-
line mRNA levels (i.e., prior to the LPS challenge) were measured in
the tumour-bearing mice and they did not investigate if the attenu-
ated neuroinflammatory response had any effect on cognitive or
affective functioning (Santos et al., 2019). Therefore, it is difficult to
assess whether tumour-mediated attenuation of neuroinflammation
has beneficial or detrimental effects on cognition and behaviour. In
another study, 67NR mammary tumours were surgically resected
14 days prior to LPS-mediated immune challenge (Emmer
et al., 2019). No changes in circulating inflammatory protein markers
were observed between control mice (vehicle injection + sham sur-
gery without removal of the mammary gland), mastectomy surgery
mice (vehicle injection + removal of the mammary gland) and tumour
mastectomy mice (tumour injection + removal of the mammary
gland). However, mRNA expression of pro-inflammatory markers -
IL-1β, TNF-α, CD68 and the IL-4 receptor α-subunit - was signifi-
cantly increased in the hippocampus of tumour-bearing mice that had
mastectomy surgery, in comparison with control mice. Of note, at the
time of mastectomy, there were no significant differences in the hip-
pocampal mRNA expression of the markers IL-1β, TNF-α, IFN-γ and
IL-6 between tumour- and vehicle-injected animals (Emmer
et al., 2019). Overall, these studies indicate that the hippocampus is
particularly vulnerable to the presence of a peripheral tumour and is
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likely very susceptible to off-target actions of tumour-induced sys-
temic inflammation. Therefore, much of the cognitive and affective
disturbances in people with non-CNS tumours could be the result of a
chronic low-level systemic inflammation that affects key brain struc-
tures involved in memory and the regulation of mood, such as the hip-
pocampus (Figure 2).
4 | HYPOTHALAMUS
The hypothalamus maintains essential physiological processes, includ-
ing sleep, growth, metabolism, reproduction, body temperature, stress
response, reward, feeding and circadian rhythms, mainly via the secre-
tion of neurotransmitters. The disruption of many of these processes
is linked to tumour initiation and progression (Masri &
Sassone-Corsi, 2018). The hypothalamus is divided into three main
regions (supraoptic, tuberal and mammillary) and three areas (para-
ventricular, medial and lateral). Each zone within the hypothalamus
contains specific subsets of neurons, also known as nuclei, with spe-
cialised functions. In the context of cancer-associated neurological
dysfunction, only a subset of hypothalamic nuclei have been investi-
gated thus far, including the lateral nuclei (involved in sleep, metabo-
lism and arousal via hypocretin/orexin [HO]-producing neurons), the
paraventricular nucleus within the supraoptic medial hypothalamus
(involved in the hypothalamic–pituitary–adrenal [HPA]-mediated
stress response) and the suprachiasmatic nuclei (SCN), within the
medial anterior hypothalamus (involved in regulating the vast majority
of processes within the human body according to a 24-h cycle, known
as the circadian rhythm) (Hall & Guyton, 2011) (Figure 3a).
4.1 | HO neurons in the lateral nuclei
Sleep disturbances, especially insomnia, are a common problem in
people with extracranial cancers prior to, during and after antineoplas-
tic therapy (Fiorentino & Ancoli-Israel, 2007). Unfortunately, poor
sleep has been correlated with impaired ‘quality-of-life’ scores, meta-
static spread and even increased mortality in cancer patients (Collins
et al., 2017; Palesh et al., 2014). Thus, it appears that tumour growth
promotes unhealthy sleep patterns, and reciprocally, poor sleep can
further stimulate cancer progression (Walker & Borniger, 2019).
Moreover, sleep disruption has also been associated with weight gain,
metabolic dysfunction and the development of a chronic inflammatory
state, which could further contribute to cancer progression (Walker &
Borniger, 2019). However, the underlying mechanisms remained
unclear until Borniger et al. (2018) investigated the involvement of
the brain in cancer-associated sleep disruption and metabolic dysfunc-
tion (Borniger et al., 2018).
Borniger et al. (2018) observed a marked increase in the circulat-
ing levels of IL-6 in mammary tumour-bearing mice (67NR), in con-
junction with a disrupted sleeping pattern. These tumour-induced
changes were associated with aberrant activity of HO-producing neu-
rons (Borniger et al., 2018). Lateral hypothalamic HO neurons project
throughout the brain to regulate a variety of functions, including
F IGURE 2 Peripheral tumour growth may affect the hippocampus, primarily via systemic inflammation. Increased levels of circulating
inflammatory cytokines (e.g., IL-6, TNF-α and IL-1β), in response to peripheral tumour growth, appear to indirectly trigger an inflammatory
response in the hippocampus. Because peripheral tumour growth is capable of altering various organ systems (e.g., hepatic metabolism, gut
microbiome and spleen myeloid immune cell populations), tumour-derived signals are likely to be amplified and propagated to the brain via
modulation of peripheral tissue physiology. In addition, tumour-induced systemic inflammation has been linked to a reduction in hippocampal
neurogenesis, as well as the decreased expression of brain-derived neurotrophic factor (BDNF) and COX-2. Whereas the communication
between the periphery and the brain is thought to occur via neural and humoral signalling, the exact mechanism is still unclear. Figure was created
with BioRender.com
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motivation, wakefulness, anxiety and reproductive behaviour. Further-
more, HO neurons send projections to various sympathetic output
nuclei, which makes them reciprocally sensitive to metabolic signals
arriving from the periphery, including leptin, ghrelin, glucose, pH and
CO2 (Sakurai, 2007). Inhibition of HO neuron signalling, using a dual
HO receptor antagonist, almorexant, ameliorated the observed sleep
abnormalities, but not the IL-6-mediated peripheral inflammation
(Borniger et al., 2018). These results indicate a link between peripheral
tumour growth and dysregulation of central neuromodulators
involved in maintaining healthy sleep/wake cycles (Figure 3b).
In general, sleep abnormalities have been shown to affect
neuronal activity and connectivity across multiple brain regions,
including the dorsolateral and medial prefrontal cortex (PFC),
thalamus, posterior cingulate cortex (PCC) and hypothalamus. The
heterogeneous array of potential brain changes, including alterations
in one's attention span, working memory, emotion, reward and hippo-
campal learning, can result in disruption of human behaviour across
nearly all domains of cognition and affection (Krause et al., 2017). The
extent to which sleep deprivation affects the brain depends on several
factors, including other co-morbidities, gender, coping mechanisms
F IGURE 3 Effects of peripheral tumour growth on hypothalamic functions. (a) The hypothalamus is divided into three main areas
(paraventricular, medial and lateral) that each contains neuronal subsets with essential physiological functions, including sleep, metabolism, stress
response and circadian rhythms. (b) Tumour-induced activation of hypocretin/orexin (HO)-secreting neurons, within the lateral hypothalamus,
was shown to cause sleep and metabolic disruption. Over time, HO neuron activation could contribute to affective disturbances in people with
extra-cranial cancers. (c) The hypothalamic–pituitary–adrenal (HPA) axis, which originates in the paraventricular nucleus of the hypothalamus, is
activated by tumour-secreted factors, such as corticotropin-releasing hormone (CRH) and IL-6, as well as input from activated neuronal
populations, such as HO neurons. In the presence of neoplastic growth, the HPA negative feedback loop is disrupted, which increases circulating
levels of cortisol (CORT) and decreases dendritic branching and hippocampal volume, likely causing neuropsychological and neurocognitive
disturbances. (d) Disruption of circadian rhythms, regulated by the suprachiasmatic hypothalamic nuclei, is frequently reported in people with
extracranial tumours. In rodents, gene expression changes have been observed in core clock-regulating genes (e.g., Clock and Per1), which caused
endocrine and immune rhythm dysfunction. Circadian clock dysfunction is likely to cause fatigue in people with non-CNS tumour growth and
potentially affective and cognitive disturbances. Figure was created with BioRender.com
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and cognitive reserve (Krause et al., 2017). Hypothalamic HO neurons
send excitatory projections to the paraventricular nucleus of the
thalamus, the arcuate nucleus, the VTA (which contains dopaminergic
neurons), the locus coeruleus (which contains noradrenergic
neurons), dorsal raphe (which contains serotonergic neurons) and
tuberomammillary nucleus (which contains histaminergic neurons)
(Sakurai, 2007). HO neurons not only regulate neurotransmitter
release but also modulate calcium-mediated synaptic plasticity via
their G protein-coupled receptors (GPCRs), OX1 and OX2 (Kukkonen
& Leonard, 2014). Moreover, HO neurons are strongly connected to
the autonomic output nuclei in the brainstem, the sympathetic ner-
vous system (SNS) and, most importantly, the HPA axis
(Sakurai, 2007). Indeed, optogenetic stimulation of HO neurons was
shown to activate the HPA axis, resulting in increased levels of
circulating glucocorticoids (Bonnavion et al., 2015). This suggests that
tumour-induced activation of HO-producing neurons in the hypothal-
amus could lead to sleep disturbances and, over time, contribute to
the affective and cognitive disturbances reported in people with
non-CNS tumours (Li et al., 2020) (Figure 3b).
People that develop peripheral cancers often suffer from meta-
bolic dysfunction, which can manifest as weight loss, anorexia, skeletal
muscle wasting, atrophy of adipose tissue and cancer-associated
cachexia. Cancer cachexia is multifactorial and is characterised by
ongoing, unintentional weight loss and progressive functional impair-
ment. Unlike previously suggested, cancer-associated weight loss also
occurs in pretreatment cancer patients, as weight loss is observed in
up to 34% of patients at the time of diagnosis, across various different
cancer types and even in early stage cancers (Stage I —17.6%)
(Gannavarapu et al., 2018). This phenomenon has been predominantly
blamed on the inflammatory side effects of tumour growth, although
clinical trials with anti-inflammatory agents show limited effects (Cole
et al., 2018). In the same study mentioned above by Borniger
et al. (2018), non-metastatic mammary tumour growth caused an
increase in circulating levels of IL-6, alongside impaired hepatic
glucose processing (Borniger et al., 2018). However, blocking IL-6
signalling using a monoclonal antibody did not rescue the observed
hepatic abnormalities. Given the ability of HO neurons to also regu-
late metabolism, the authors hypothesised the involvement of HO
neurons. Here, blocking HO signalling using the antagonist,
almorexant, attenuated the hyperglycaemia and partly rescued the
expression of genes involved in gluconeogenesis and glycolysis (ldha,
gck and slc2a4) (Borniger et al., 2018).
In the human body, the orexigenic peptide ghrelin excites
HO-producing neurons, whereas leptin inhibits their activity. Although
ghrelin is predominantly produced and secreted by the stomach,
ghrelin-producing neurons and their receptors have been identified in
the CNS, including the hypothalamus (So et al., 2018). Previous studies
have shown that central and peripheral administration of ghrelin to
rodents activates various brain regions, including the hypothalamus,
indicating that peripheral ghrelin can reach the brain (Cabral
et al., 2015). Interestingly, ghrelin has been shown to be highly
expressed in a multitude of extracranial cancer tissues such as colorec-
tal, liver, pancreatic, thyroid, ovarian, prostate and breast cancers,
although the data remain controversial (Soleyman-Jahi et al., 2019). This
peripheral ghrelin imbalance could potentially cause a disruption in the
negative feedback loop of HO neurons. Moreover, in the hippocampus,
ghrelin interacts with the growth hormone secretagogue receptor
(GHSR-1a), causing a conformational change in the receptor and leading
to a wide array of physiological changes. Because GHSR expression is
relatively high within the hippocampus, ghrelin was shown to promote
LTP, spatial learning and memory formation (Mainardi et al., 2015;
Ribeiro et al., 2014). In contrast, hyperactivation of hypocretin neurons
has also been shown to cause insomnia, panic attacks, anxiety and
depression (Nollet et al., 2012). Although a promising target to explain
neurological dysfunction in pretreatment cancer patients, ghrelin, and
its actions on HO-secreting neurons within the hypothalamus, has not
been directly linked to the phenomenon of CRCI.
Whereas HO-secreting neurons are activated by ghrelin and
hypoglycaemia, their activity is inhibited by the production of leptin
(Yamanaka et al., 2003). Borniger et al. (2018) observed significantly
reduced serum leptin levels in non-metastatic 67NR mammary
tumour-bearing mice, in conjunction with aberrant HO neuron activity
(Borniger et al., 2018). Leptin, a key peripheral signal, is also known to
regulate the medio-basal hypothalamus. The medio-basal hypothala-
mus includes the arcuate nucleus and median eminence and contains
crucial neuronal populations that control food intake and energy
expenditure, including leptin-sensitive neuropeptide Y (NPY), agouti-
related protein (AGRP) and GABA (NAG)-containing neurons and pro-
opiomelanocortin (POMC)-expressing neurons (Pan & Myers, 2018).
In addition to neuronal cell populations, the microglial cells within the
medio-basal hypothalamus are highly responsive to inflammatory
stimuli and metabolic perturbations (Valdearcos et al., 2019). Although
microgliosis within the medio-basal hypothalamus is mostly studied in
the context of obesity, Burfeind, Zhu, Norgard, Levasseur, Huisman,
Michaelis, et al. (2020b) recently demonstrated that microgliosis
within the medio-basal hypothalamus also occurs during cancer
cachexia. The authors used a mouse model of pancreatic ductal
adenocarcinoma, which is nearly always accompanied by cachexia.
Here, microglia were shown to respond to tumour-derived factors and
infiltrate the medio-basal hypothalamus, where they assumed an
activated state. Interestingly, microglial depletion, or prevention of
their activation using an antagonist against the colony stimulating
factor 1 receptor, worsened cachexia. Moreover, antagonist-treated
animals had significantly higher levels of circulating cortisol, which
indicates activation of the HPA-axis. Overall, this study demonstrates
a protective role for microglial activation within the hypothalamus in
the context of cancer-associated cachexia (Burfeind, Zhu, Norgard,
Levasseur, Huisman, Michaelis, et al., 2020b). However, the effects of
localised microgliosis on cognitive and affective functioning in
patients with cancer cachexia are yet to be determined.
4.2 | HPA axis in the paraventricular nuclei
As previously mentioned, many hypothalamic processes are
influenced by the HPA axis, which is primarily driven by the
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paraventricular nucleus of the hypothalamus (DeMorrow, 2018). The
HPA axis is known to be activated by internal and external stimuli,
which are perceived as a threat by higher order cognitive centres.
These regions identify the threat to homeostasis and send excitatory
signals to the hypothalamus to initiate the synthesis and release of
corticotrophin-releasing hormone (CRH) and arginine vasopressin
(AVP). CRH is transported to the anterior pituitary gland via the hypo-
physial portal blood vessels, which connect the hypothalamus and
the pituitary gland. Simultaneously, AVP is transported to the
posterior pituitary gland via axonal transport. Once CRH and AVP
reach the pituitary gland, the hormones act synergistically to stimulate
the production and secretion of the adrenocorticotropic hormone
(ACTH) from POMC-expressing corticotropic cells. ACTH is then
released into the general circulation and makes its way to the adrenal
glands, located on top of the kidneys. Here, ACTH induces the synthe-
sis of fast-acting catecholamines, such as noradrenaline and
adrenaline and the more slow-acting glucocorticoids, such as cortisol,
which are released into the bloodstream. Under normal circum-
stances, glucocorticoid secretion is regulated via a negative feedback
system. However, disturbances in the HPA signalling cascade are
common in a variety of chronic diseases, such as cancer (Herman
et al., 2016). Basal levels of HPA-axis hormones are necessary to
maintain homeostatic organ and tissue function, whereas the smallest
perturbations in steroid concentration can have a serious impact on
the body's physiology. Glucocorticoids act via glucocorticoid (Type II)
and mineralocorticoid (Type I) receptors to which they bind with dif-
ferent affinities. The mineralocorticoid receptor has a high affinity for
glucocorticoids and is heavily occupied during the diurnal cycle. How-
ever, stress-induced elevations of the glucocorticoid concentrations
increase the occupation of the lower-affinity glucocorticoid receptors
(McEwen, 2007). On the other hand, stress-induced catecholamines
can bind, with varying affinities, to G protein-coupled α- and β-adren
ergic receptor subtypes to regulate SNS tone. Adrenergic receptors
are expressed on a wide variety of tissues in the body and play major
roles in modulating physiological processes, including smooth muscle
cell constriction, myocardial contractility, heart rate and immune sys-
tem function (Maletic et al., 2017).
Aberrant activation of the HPA axis and the subsequent produc-
tion of catecholamines and glucocorticoids, which are strong regula-
tors of metabolic state, immune function and circadian rhythms, are
commonly reported in people with cancer (Weinrib et al., 2010).
Psychological distress, which can begin with a cancer diagnosis and
continue during treatment, is commonly experienced by people with
cancer (Annunziata et al., 2011). Stress hormones, both cortisol and
noradrenaline, have been shown to have a severe impact on disease
progression and prognosis (Volden & Conzen, 2013). Thaker
et al. (2006) were one of the first to show that elevated circulating
levels of catecholamines resulted in increased tumour burden, angio-
genesis and invasiveness of ovarian carcinoma cells in an orthotopic
mouse model (Thaker et al., 2006). These findings were later corrobo-
rated in other cancer mouse models, which showed accelerated
tumour progression in the presence of stress hormones, caused by
disrupting anti-tumour immunity and other endocrine effects on
tumour metabolism, angiogenesis, oncogenesis and DNA repair
(Flaherty et al., 2017; Zhang et al., 2019). In humans with adrenocorti-
cal carcinoma, glucocorticoid excess was associated with low amounts
of tumour-infiltrating lymphocytes and poor overall survival
(Landwehr et al., 2020). In turn, altered cortisol responses and aber-
rant adrenergic signalling in cancer patients have also been correlated
with neurological issues, such as cancer-related fatigue, anxiety,
depression and potentially CRCI (Andreotti et al., 2015; Schmidt
et al., 2016; Weinrib et al., 2010).
The HPA axis not only regulates the immune system, but the
reverse also happens. For example, immune-neuroendocrine feedback
has been shown to play a role in viral infections. Immune cells can
dampen their own activity via the production of pro-inflammatory
cytokines and the subsequent release of glucocorticoid hormones,
which, in turn, attenuates the production of pro-inflammatory media-
tors by immune cells (Silverman et al., 2005). A similar mechanism
could be happening in people with cancer prior to receiving treatment.
For example, the pro-inflammatory cytokine, IL-6, is a potent inflam-
matory cytokine released by various cells within the TME, and
increased serum levels of IL-6 have been demonstrated in various can-
cers (Masjedi et al., 2018). IL-6 was shown to be a potent activator of
the adrenal axis following LPS-mediated immune activation (Bethin
et al., 2000). Moreover, in colon or pancreatic tumour-bearing mice,
an IL-6-mediated decrease in hepatic ketogenesis was associated with
a glucocorticoid-mediated stress response, decreased anti-tumour
immunity and decreased immunotherapy efficacy (Flint et al., 2016).
In patients undergoing glucocorticoid therapy, serum levels of IL-6 are
significantly reduced (Fujio et al., 2016). However, in the presence of
neoplastic cell growth, the HPA negative feedback loop appears
disrupted, which is likely to lead to the observed neurocognitive and
neuropsychological disturbances in cancer patients. Interestingly, IL-6
and hyperactivity of the HPA axis also play a crucial role in the
aetiology of depression. Jehn et al. (2010) found a strong correlation
between increased plasma levels of IL-6 and HPA-axis dysfunction in
cancer patients diagnosed with depression (Jehn et al., 2010). This
faulty HPA feedback system is thought to be due to desensitised glu-
cocorticoid receptors in the brain. Pro-inflammatory cytokines, includ-
ing those produced in response to tumour growth, contribute to this
desensitisation of glucocorticoid receptors by impairing the nuclear
translocation and/or transcriptional function of these receptors
(Silverman & Sternberg, 2012). Tumour cells, in conjunction with rec-
ruited immune cells, not only produce inflammatory cytokines but also
secrete various other bioactive peptides that can affect the HPA axis.
For example, intra-tumour production of CRH has been reported in
human ovarian cancer (Minas et al., 2007) and in human melanoma
cells (Sato et al., 2002). Prolonged activation of the HPA axis and
chronic exposure to increased concentrations of glucocorticoids can
have a range of pathological effects on the brain, such as decreased
hippocampal volumes and decreased dendritic branching of immature
dentate granule cells (Dioli et al., 2019) (Figure 3c). Another frequently
reported side effect of HPA-axis dysfunction is the disruption of
circadian rhythms, which are regulated by the SCNs within the hypo-
thalamus (Dumbell et al., 2016).
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4.3 | Suprachiasmatic nuclei
The master regulator of the circadian system is located within the
hypothalamus, known as the paired SCN. The SCN regulate neuronal
activity, body temperature, hormone release, immune function, sleep
and feeding in a 24-h cycle based on light–dark input from the retinal
ganglion cells (Dumbell et al., 2016). Cancers have been linked to
disruptions in the circadian rhythm (Sulli et al., 2019). Moreover,
disruption of the circadian rhythm is strongly associated with brain
dysfunction, suggesting that tumour-induced disruption of the
circadian rhythm could alter brain function in cancer patients (Cash
et al., 2015; Logan & McClung, 2019). For example, people with
breast cancer display altered levels of circulating leukocytes and
melatonin and report disturbances in their sleep–wake cycle. These
observations were associated with behavioural co-morbidities,
including fatigue and memory impairment (Ahles & Root, 2018;
Payne, 2011).
Using a mouse model of lung adenocarcinoma, Masri
et al. (2016) showed that tumour growth can disrupt the circadian
metabolic rhythm as assessed by transcriptomic and metabolic anal-
ysis of the liver. Here, tumour growth in a distal organ led to alter-
ations in liver metabolism, demonstrated by inhibition of hepatic
insulin signalling, increased glucose production and deregulated lipid
metabolism, which likely further drive tumourigenesis (Hadadi
et al., 2020; Kinouchi & Sassone-Corsi, 2020). Whereas the authors
stated that lung adenocarcinoma did not affect the core compo-
nents of the circadian clock, they did not examine any core compo-
nents, such as the hypothalamus (Masri et al., 2016). Thus, Sullivan
et al. (2019) further explored the impact of mammary tumour
growth on central circadian rhythm regulation (Sullivan et al., 2019).
After quantification of clock-related gene expression in the hypo-
thalamus, two core clock-regulating genes (Clock and Per1) and four
additional clock-related genes (Aanat, Camk2a, Creb1 and Mntr1a)
were found to be differentially expressed in mammary tumour-
bearing mice (67NR). Alongside hypothalamic gene expression
changes, the researchers observed a significantly higher percentage
of running wheel locomotor activity during the light phase of a
14:10 light–dark cycle in tumour-bearing mice, in comparison with
non-tumour-bearing controls and tumour-resected animals. More-
over, the normal 24-h rhythm in circulating corticosterone and cir-
culating neutrophils (CD11b+/Ly6G+) was absent in tumour-bearing
mice (Sullivan et al., 2019). Their findings confirm that peripheral
tumour growth, independent of harsh cancer treatments, can disrupt
the central molecular clock, as well as the physiological rhythms of
the endocrine and immune systems (Figure 3d). They provide a
potential explanation for the behavioural co-morbidities seen in can-
cer patients. However, the exact mechanism of how tumour growth
causes circadian rhythm dysregulation is still unclear but is likely to
be due to tumour-secreted factors, such as inflammatory cytokines.
For example, abnormal diurnal cortisol rhythms in people with epi-
thelial ovarian cancer prior to treatment were associated with
increased levels of the pro-inflammatory cytokine, IL-6, and overall
decreased survival (Schrepf, Thaker, et al., 2015) (Figure 3d).
5 | MIDBRAIN VENTRAL
TEGMENTAL AREA
The midbrain ventral tegmental area (VTA) is commonly known for its
role in motivational behaviours and in the brain's reward system.
However, more recently, the VTA has gained attention because of its
ability to modulate tumour progression via the production of the neu-
rotransmitter, dopamine (Ben-Shaanan et al., 2018; Xu et al., 2020).
The VTA is one of the primary sources of dopamine within the brain.
Dopamine is important in regulating motivation, mood and cognition
and also exerts various actions in the periphery, such as blood pres-
sure regulation and modulation of both the innate and adaptive
immune systems (Zhang et al., 2017). Dopamine primarily mediates its
effects via dopamine receptors, which are GPCRs and can be divided
into two subgroups, D1-like (DRD1) and D2-like (DRD2), depending
on their binding affinities. Dopamine synthesis relies on hydroxylation
of L-tyrosine by tyrosine hydroxylase (TH), resulting in L-DOPA pro-
duction. This step is followed by the decarboxylation of L-DOPA by
the aromatic amino acid decarboxylase (DOPA decarboxylase) (Matt
& Gaskill, 2020). Whereas the dopamine receptors and proteins
required for dopamine synthesis are primarily expressed in dopami-
nergic neurons, various immune cells and cells from peripheral tissues
express the required receptors and enzymes for dopamine activity
and synthesis. For example, T lymphocytes express all dopamine
receptors, as well as TH, the dopamine transporter (DAT) and
catechol-O-methyltransferase (COMT), which is necessary for the
degradation of dopamine. This indicates that T cells also have the
capacity to take up, synthesise, store and release dopamine (Pacheco
et al., 2009). Various immune functions, including cytokine secretion,
chemotaxis and cell adhesion, are regulated via dopamine. Besides
directly responding to dopamine, immune cells are also indirectly
influenced by dopaminergic regulation within the CNS. Hyper-
activation of the central dopaminergic system in the mouse VTA was
shown to enhance phagocytic activity of splenic dendritic cells and
macrophages (Ben-Shaanan et al., 2016). In turn, immune dysfunction
is likely to affect dopaminergic signalling in both the CNS and periph-
ery (Mackie et al., 2018).
Until now, cancer biologists have mainly focused on peripheral
dopamine and its receptors (Zhang et al., 2017), and therefore, the
central dopaminergic system has received little attention for its ability
to modulate tumour progression. Several epidemiological studies have
suggested that people with schizophrenia, associated with hyper-
reactive dopaminergic systems, are relatively protected from develop-
ing cancer (Li et al., 2018). However, gender and the type of cancer
studied are two important variables because men showed a significant
decrease in the incidence of colorectal cancer, whereas women with
schizophrenia may have a higher risk of developing breast cancer
(Wu Chou et al., 2017). Similarly, the development of Parkinson's
disease, marked by declining dopamine levels, was associated with a
lower risk of smoking-related cancers and a higher risk of developing
malignant melanoma and breast cancer (Driver et al., 2007).
Smaller primary tumours, reduced angiogenesis and a reduced
metastatic potential of the tumour were observed following mammary
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tumour implantation (MADB106) in Wistar APO-SUS rats with high
dopaminergic reactivity, compared with those in APO-UNSUS rats
with low dopaminergic reactivity (Teunis et al., 2002). More recently,
chemogenetic activation of VTA-dopaminergic neurons was shown to
reduce primary tumour volumes in two lung cancer mouse models
(LCC and B16 melanoma) (Ben-Shaanan et al., 2018). To study how
activation of VTA-dopaminergic neurons within the brain could signal
to the primary tumour, the SNS was ablated using the neurotoxin
6-hydroxydopamine (6-OHDA). In mice that received 6-OHDA, acti-
vation of VTA-dopaminergic neurons no longer reduced tumour bur-
den. The authors further showed that VTA activation altered the
levels of noradrenaline in the bone marrow. Subsequently, this
reduced the number of myeloid-derived suppressor cells (MDSCs),
which normally promote tumour growth via stimulation of angiogene-
sis and inhibition of anti-tumour immunity. These findings indicate
that central VTA stimulation, and thus enhanced levels of reward and
motivation in mice, can modulate the immune system via
SNS-mediated suppression of MDSCs (Ben-Shaanan et al., 2018). This
emphasises the important translational implications of these rodent
studies and suggests that those people who keep active, remain moti-
vated and receive enough emotional support and VTA reward system
activation after a cancer diagnosis may show reduced tumour growth/
aggressiveness or better responses to chemotherapy treatments
(Mehta et al., 2019; Van der Gucht et al., 2020).
The effects of stress and the activation of neural circuitry control-
ling emotions on tumour progression has been investigated in breast
tumour-bearing mice (MDA-231, MCF-7 and 4T1) by subjecting them
to unpredictable chronic mild stress (UCMS) (Xu et al., 2020).
TH-positive neuronal terminals within the medial PFC (mPFC), which
receives dopaminergic afferents from the VTA, were activated via
optogenetic stimulation. Here, optogenetic activation of TH-positive
terminals within the mPFC rescued anxiety-like behaviour in UCMS
stressed tumour-bearing mice. Furthermore, repeated optogenetic
stimulation of VTA-TH inputs in the mPFC attenuated the enhanced
tumour progression observed in chronically stressed mice. The
authors attributed this beneficial effect to reduced serum levels of
the stress-related hormones, noradrenaline and corticosterone, in the
VTA-TH-activated mice (Xu et al., 2020).
Given the known roles of the VTA in regulating mood, the studies
discussed above have uncovered a potential physiological mechanism
underlying how a patient's psychological status may modulate anti-
tumour immunity and cancer progression. However, could modulation
of tumour progression by the VTA-dopaminergic axis and the SNS
have physiological consequences that act back on the brain? In chronic
neurological conditions, such as depression, the SNS is known to be
continuously activated without the balancing counteractions of the
parasympathetic nervous system. This results in immune system
activation and increased levels of systemic pro-inflammatory cytokines,
which is often reported in patients with depression (Won &
Kim, 2016). Therefore, chronic activation of the SNS by the presence
of a peripheral tumour could prime the immune system and increase
peripheral inflammation that, over time, may lead to depression
in people with untreated cancers (Sforzini et al., 2019). Indeed,
inflammation-driven alterations to metabolic pathways, such as the
indoleamine 2,3-dioxygenase (IDO)-kynurenine and tetrahydrobiopte
rin (BH4) pathways, have been shown to cause substantial alterations
in the synthesis of dopamine, 5-HT and noradrenaline and are likely to
be the cause of depressive symptoms in cancer patients (Vancassel
et al., 2018). In a mouse model inoculated with B16F10 melanoma
cells, for example, the tumours induced depressive-like behaviour, as
assessed by the tail suspension test, and led to increased levels of IL-6
and TNF-α in the brain (Lebeña et al., 2014). This corresponded with a
decrease in dopaminergic activity in the striatum and a decrease in
5-HT in the PFC, with both regions receiving dopaminergic inputs from
the VTA (Lebeña et al., 2014).
These alterations in monoamine turnover have been ascribed to
tumour-induced dysfunction of metabolic processes within the brain.
With this in mind, Kovalchuk et al. (2018) performed direct flow
injection/MS (DI-MS) to assess the effects of extra-cranial tumour
growth (including lung cancer, pancreatic cancer and sarcoma) on
the brain metabolome in mice (Kovalchuk et al., 2018). The authors
demonstrated that non-CNS tumour growth affected protein biosyn-
thesis, and amino acid and sphingolipid metabolism. Of five different
pathways that were commonly affected in all three cancer types,
protein biosynthesis was significantly up-regulated in all three
groups. Moreover, amino acid metabolism (including phenylalanine
and tyrosine), as well as valine, leucine and isoleucine degradation,
was commonly affected (Kovalchuk et al., 2018). Decreased amino
acid levels or the deregulation of their metabolic machinery in the
brain can cause neuronal death and apoptosis. Moreover, the
observed alterations in catecholamine biosynthesis and increased
levels of phenylalanine and tryptophan are known to cause neuro-
transmitter imbalances in levels of 5-HT, dopamine and noradrena-
line (Xu et al., 2016). These findings further support the notion that
tumour-induced inflammation can cause dysfunctions in monoamin-
ergic systems, which in turn can lead to altered neural signalling in
the affected brain regions (Figure 4).
6 | BRAIN STEM
Peripheral tumours are also likely to modulate the CNS by influencing
the vagus nerve. The vagus nerve is the main component of the
parasympathetic nervous system and relays inflammatory, satiety and
metabolic cues to the brain. The vagal afferent fibres terminate within
the nucleus tractus solitarius (NTS) in the brain stem, which further
projects the information to higher brain regions including the hypo-
thalamus, locus coeruleus and amygdala (Breit et al., 2018). The vagus
nerve has been implicated in various diseases, including cancer.
Elevated vagal tone, measured by heart rate variability (HRV), is
thought to exert a protective effect on cancer prognosis via the
inhibition of oxidative stress, inflammation and sympathetic activity.
However, rodent studies investigating the effects of vagal denerva-
tion have uncovered both protective and detrimental effects on
tumour initiation, progression and metastasis (Partecke et al., 2017;
Zhao et al., 2014).
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In response to peripheral cancers, the vagus nerve is thought
to inform the brain about tumour growth via inflammatory signals.
In response, the brain can modulate tumour growth via the neuro-
endocrine and immune systems (Giese-Davis et al., 2015). Activa-
tion of the vagus nerve has been recorded electrophysiologically
following peripheral administration of the pro-inflammatory cyto-
kines, IL-1β and TNF-α (Tsaava et al., 2020). On one hand, vagal
nerve stimulation (VNS) has been shown to be predominantly neu-
roprotective and ameliorates LPS-induced cognitive dysfunction in
mice (Huffman et al., 2019). On the other hand, stress, which is
common in cancer patients, inhibits the vagus nerve and has dele-
terious effects on the gastrointestinal tract and gut microbiota
(Bonaz et al., 2018). As such, the vagus nerve also serves as a
connection between the enteric nervous system (ENS) and the
CNS, also known as the gut–brain axis. The gut–brain axis is
responsible for monitoring the body's physiological homeostasis by
connecting emotional and cognitive brain areas to peripheral func-
tions, such as immune activation and enteroendocrine signalling.
Neuroactive compounds, such as ACh and 5-HT, released by the
gut microbiota reach the CNS via the blood and circumventricular
organs or via the vagus nerve (Bonaz et al., 2018). Altered compo-
sitions of the gut microbiota have been linked to neurological com-
plications, including depression and anxiety (Breit et al., 2018).
Given that dysbiosis of the gut microbiome has been reported in
cancer patients, gut–brain signalling via the vagus nerve could be
another potential pathway for neurological dysfunction in
F IGURE 4 Peripheral tumours may disrupt monoaminergic neurotransmitter synthesis in the midbrain ventral tegmental area (VTA). The
midbrain VTA is not only modulated by tumour progression, via the production of dopamine, but is also reciprocally affected by peripheral tumour
growth. Tumour-induced inflammation and immune cell activation caused alterations to metabolic pathways (e.g., indoleamine 2,3-dioxygenase
[IDO]–kynurenine), which has a marked effect on the synthesis of monoaminergic neurotransmitters, such as dopamine and 5-HT. Enhanced
tryptophan (Trp) breakdown, which is reflected by an increase in circulating kynurenine (Kyn), is observed in various peripheral cancers. Trp
breakdown is mainly mediated by IDO-1, which is expressed by antigen-presenting cells (e.g., macrophages and dendritic cells) in response to
inflammatory stimuli (e.g., IFN-γ, TNF-α, COX-2 and PGE2). Quinolinic acid (QUIN), also a tryptophan by-product, is a selective agonist of the
NMDA glutamate receptor. QUIN accumulation results in excitotoxicity, oxidative stress (via accumulation of ROS), neuronal cell death and
disruption of glutamatergic neurotransmission (Lugo-Huitron et al., 2013). As QUIN cannot cross the blood–brain barrier (BBB), it can only be
synthesised by resident microglia or infiltrated monocytes/macrophages (Lugo-Huitron et al., 2013). Increased levels of inflammatory markers,
ROS and reactive nitrogen species (RNS) also contribute to the oxidation of tetrahydrobiopterin (BH4). Limited bioavailability of BH4 for
phenylalanine hydroxylase (PAH), TH and tryptophan hydroxylase (TrypOH) activity drastically reduces monoamine synthesis, including 5-HT and
dopamine. Although disruption of monoamine synthesis has only been demonstrated in rodent studies, this mechanism is a likely cause of
depressive symptoms and cognitive dysfunction in people with extra-cranial tumours. Figure was created with BioRender.com
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pretreatment cancer patients, although this link is yet to be
established (Whisner & Athena Aktipis, 2019).
7 | CONCLUSION
Neurological complications can exert devastating effects on people
that develop extra-cranial cancers and can seriously affect their
quality of life, their ability to tolerate and complete complex treat-
ment regimens and could even shorten their overall survival rate.
Whereas the neurological implications of ant-ineoplastic therapies
have received a substantial amount of interest, the existence of
cognitive and affective disorders, before treatment has started, indi-
cates that the full aetiology of these complications cannot be solely
explained by the anti-cancer treatment itself. The compounding
inflammatory and overall disruptive nature of peripheral tumour
growth is now being recognised as a major challenge for the CNS
(Cerulla Torrente et al., 2020). However, our understanding of how
peripheral tumours affect critical functions within the brain is still
limited. Elucidation of the molecular mechanisms by which extra-
cranial tumours can induce affective and cognitive disorders prom-
ises to improve quality of life and treatment outcome in cancer
patients. Moreover, the development of novel targeted
neurotherapeutic agents that stimulate specific brain regions that
are deregulated in cancer will help to overcome hurdles in current
treatment strategies. In addition, holistic non-pharmacological
approaches to cancer treatment, such as mindfulness and medita-
tion, have already been shown to attenuate inflammation and
reduce stress in breast cancer patients via stimulation of the dopa-
minergic VTA (Bower et al., 2015; Dutcher et al., 2020). However,
significantly more research is needed to understand how peripheral
tumours communicate with and affect the brain (Box 1). Neuro-
immunologists and cancer biologists must work together with
oncologists and psychiatrists to develop new ways to treat the
whole body, including the brain and mind, if we are to truly beat
cancer and give people back their full quality of life after treatment,
which is very much dependent on maintaining their cognitive
health.
Box 1. Outstanding questions
1. Which (sub)types of cancer correlate with a higher risk
of developing tumour-induced affective and cognitive
disturbances?
2. What strategies can be applied in the clinic to ameliorate
affective and cognitive disturbances in cancer patients
before they receive treatment ?
3. Can the existence of affective and cognitive disorders,
before treatment, predict vulnerability to the develop-
ment of long-lasting chemotherapy-induced affective
and cognitive impairments?
4. Can the brain fully recover after having experienced
tumour-induced neurological dysfunctions (i.e., when the
tumour is no longer present)?
5. Does an event of tumour-induced neurological dysfunc-
tion earlier in life increase vulnerability to the develop-
ment of age-related neurological disorders?
7.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPSGuide to PHARMACOLOGY
(http://www.guidetopharmacology.org) and are permanently archived
in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander,
Christopoulos et al., 2019; Alexander, Cidlowski et al., 2019; Alexander,
Fabbro et al., 2019a,b; Alexander, Kelly et al., 2019a,b).
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